canagliflozin

The more recent and exciting information coming from the real-world experience in the United States, Germany, Sweden and the United Kingdom with 1.4 million diabetic patients show that canagliflozin in the US, and dapagliflozin in Europe (and Asia) also reduce death rates among diabetic patients with heart disease and even among those with no established heart disease.

Canagliflozin (CANA), the other agent in this binary study (Figure 1(a)), is sodium glucose cotransporter 2 (SGLT2) inhibitor, which was developed for DMT2 treatment by Janssen Pharmaceuticals Inc.

Release date- 23082019 - CAMBRIDGE - As the European distributor of Invokana (canagliflozin) and Vokanamet (canagliflozin and metformin), Mundipharma welcomes the news that the European Medicines Agency (EMA) has accepted the licence extension submission for these two medicines to treat stage 2 or stage 3 chronic kidney disease (CKD) and albuminuria as an adjunct to standard of care in adults with type 2 diabetes mellitus (T2DM).

- The licence extension submission for Invokana (canagliflozin) and Vokanamet (canagliflozin and metformin) to treat type 2 diabetes mellitus patients with chronic kidney disease will now be reviewed by the Committee for Medicinal Products for Human Use, Invokana and Vokanamet European distributor Mundipharma said.

The European Medicines Agency (EMA) has granted a licence extension submission to United Kingdom-based Mundipharma's Invokana (canagliflozin) and Vokanamet (canagliflozin and metformin) to treat stage two or stage three chronic kidney disease and albuminuria as an adjunct to standard of care in adults with type two diabetes mellitus (T2DM), it was reported yesterday.

In 26 cases, canagliflozin was implicated, with presentation time varying from a few hours to up to six weeks after operation.

Amputation risks also are associated with taking the SGLT2 inhibitor canagliflozin (Invokana).

Hydroxychloroquine, a drug traditionally used to treat malaria, may be as beneficial for people with diabetes as the drug canagliflozin, according to a presentation at the American Association of Clinical Endocrinologists 2019 Annual Scientific & Clinical Congress.

A retrospective cohort study and meta-analysis of four observational databases found no evidence of the increased risk of below-knee lower limb amputations for patients with T2DM treated by SGLT-2 inhibitors, in particular, with canagliflozin (42, 46).

Food and Drug Administration (FDA) has granted Priority Review for the supplemental New Drug Application (sNDA) for INVOKANA[R] (canagliflozin) to reduce the risk of end-stage kidney disease (ESKD), the doubling of serum creatinine, and renal or cardiovascular (CV) death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD).

Keywords: Diabetes, SGLT-2, dapagliflozin, canagliflozin, empagliflozin, ertugliflozin